Mevastatin‐Induced HO‐1 Expression in Cardiac Fibroblasts: A Strategy to Combat Cardiovascular Inflammation and Fibrosis

I‐Ta Lee,Chien‐Chung Yang,Yan‐Jyun Lin,Wen‐Bin Wu,Wei‐Ning Lin,Chiang‐Wen Lee,Hui‐Ching Tseng,Fuu‐Jen Tsai,Li‐Der Hsiao,Chuen‐Mao Yang

DOI: https://doi.org/10.1002/tox.24429

IF: 4.109

2024-10-23

Environmental Toxicology

Abstract:Mevastatin (MVS) is known for its anti‐inflammatory effects, potentially achieved by upregulating heme oxygenase‐1 (HO‐1), an enzyme involved in cytoprotection against oxidative injury. Nonetheless, the specific processes by which MVS stimulates HO‐1 expression in human cardiac fibroblasts (HCFs) are not yet fully understood. In this study, we found that MVS treatment increased HO‐1 mRNA and protein levels in HCFs. This induction was inhibited by pretreatment with specific inhibitors of p38 MAPK, JNK1/2, and FoxO1, and by siRNAs targeting NOX2, p47phox, p38, JNK1, FoxO1, Keap1, and Nrf2. MVS also triggered ROS generation and activated JNK1/2 and p38 MAPK, both attenuated by NADPH oxidase or ROS inhibitors. Additionally, MVS promoted the phosphorylation of FoxO1 and Nrf2, which was suppressed by p38 MAPK or JNK1/2 inhibitor. Furthermore, MVS inhibited TNF‐α‐induced NF‐κB activation and vascular cell adhesion molecule‐1 (VCAM‐1) expression via the HO‐1/CO pathway in HCFs. In summary, the induction of HO‐1 expression in HCFs by MVS is mediated through two primary signaling pathways: NADPH oxidase/ROS/p38 MAPK, and JNK1/2/FoxO1 and Nrf2. This research illuminates the underlying processes through which MVS exerts its anti‐inflammatory effects by modulating HO‐1 in cardiac fibroblasts.

toxicology,environmental sciences,water resources